Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oculis Holding AGOISE:OCS -1.10%26 Buyback Yield % is -4.19 as of Jul. 31, 2026. GuruFocus rates OISE:OCS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, Oculis Holding AG ranks better than 61.63% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Oculis Holding AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OISE:OCS vs RIGL, GYRE, SGP: Buyback Yield % Comparison
For the Biotechnology subindustry, Oculis Holding AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oculis Holding AG Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Oculis Holding AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oculis Holding AG (OISE:OCS) has a Buyback Yield % of -4.19 as of Jul. 31, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #282 out of 735 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Oculis Holding AG's Buyback Yield % too high?
Oculis Holding AG's current Buyback Yield % is -4.19. Based on the distribution chart, Oculis Holding AG ranks #282 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Buyback Yield % compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #282 out of 735 companies for Buyback Yield %. This puts Oculis Holding AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current Buyback Yield % is -4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OISE:OCS) has a current Buyback Yield % of -4.19. The current Buyback Yield % is -4.19. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Oculis Holding AG (OISE:OCS), the current Buyback Yield % is -4.19 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score
Get the complete analysis for OISE:OCS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:OCS has been successfully added to your 
